A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia

Leukemia

Volumn 10, Issue 5, 1996, Pages 766-768

  Amadori, S ^a,b   Picardi, A ^a   Fazi, P ^a   Testi, A M ^a   Petti, M C ^a   Montefusco, E ^a   Mandelli, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Carboplatin; Chemotherapy; Myelogenous leukemia

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE; ANTIBIOTIC AGENT; CARBOPLATIN; CIPROFLOXACIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG MYCOSIS; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0029924785     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Champlin RE, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551-1562.
2. Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989; 37: 162-190.
3. Meyers FJ, Welborn J, Lewis JP, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7: 173-178.
4. Vogler WR, Harrington DP, Winton EF, Lazarus HM, Bennett JM, Cassileth PA, Oken MM. Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia 1992; 6: 1072-1075.
5. Archimbaud E, Anglaret B, Thomas X, Devaux Y, Ffrench M, Sebban C, Troncy J, Fiere D. Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. Leukemia 1992; 6: 776-779.
6. Sanz MA, Sanz GF, Martinez JA, Senent L, Lopez F, Palau J, Martin C, Jerque I. Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia. Ann Oncol 1992; 3 (Suppl. 3): 39-42.
7. Mabel JA, Little AD. Therapeutic synergism in murine tumors for combinations of cis-diamine-dichloroplatinum with VP-16-213 or BCNU. Proc Am Assoc Cancer Res 1979; 20; 230.
8. Bergerat JP, Drewinko B, Corry P, Barlogie B, Ho DH. Synergistic lethal effect of cis-dichlorodiamine platinum and 1 β-D-arabinofuranosyl cytosine. Cancer Res 1981; 41: 25-30.
9. Silverman L, Jacobs R, Norton L. Combination chemotherapy for refractory lymphoma with cytosine arabinoside, cisplatin and etoposide: APE. Proc Am Soc Clin Oncol 1984; 3: 246.
10. Wimmer R, Weiner M, Strauss L. Treatment of pediatric patients for relapsed Hodgkin's disease (HD) with cytosine arabinoside (A), cisplatin (P), and etoposide (E). Proc Am Soc Clin Oncol 1987; 6: 191.
11. Vaughan WP, Karp JE, Burke PJ. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984; 64: 975-978.
12. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning CD, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG. Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-210.
14. Herzig RH, Lazarus HM, Wolff SN, Philips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission induction of acute non-lymphoblastic leukemia. J Clin Oncol 1985; 3: 992-997.
15. Walters RS, Kantarijan HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988; 62: 677-682.
16. Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F. Mitoxantrone, etoposide and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991; 9: 1210-1214.
17. Daenen S, Lowenberg B, Sonneveld P, van Putten WLJ, Verhoef G, Verdonck LF, van Veldhoven M, Huijgens PC. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Leukemia 1994; 8: 6-10.
18. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, Troncy J, Assouline D, Fiere D. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13: 11-18.
19. Allen SL, Coleman M. Terminal-phase chronic myelogenous leukemia: approaches to treatment. Cancer Invest 1985; 3: 491-503.
20. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 1988; 62: 672-676.
21. Martinez JA, Martin G, Sanz GF, Sempere A, Jarque I, de la Rubia I, Sanz MA. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 1991; 9: 39-43.